Seattle Genetics, Takeda's cancer drug meets main goal in trial

September 29, 2014 11:51 AM

12 0

Seattle Genetics, Takeda's cancer drug meets main goal in trial

(Reuters) - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.

Also read: FDA expands approval for Pfizer cancer drug Sutent

Read more

To category page

Loading...